Lupus erythematosus

This study is testing the meningococcal B vaccine (Bexsero) in children and young adults aged 2 to 25 who have autoimmune rheumatic diseases like juvenile arthritis or lupus. Researchers want to see if the vaccine triggers a strong immune response and if it is safe, especially fo…

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This study tests the safety and immune response of the 20-valent pneumococcal vaccine (PCV20) in children, adolescents, and young adults aged 2-25 with autoimmune rheumatic diseases like juvenile arthritis. All 114 participants will receive one dose of PCV20, and researchers will…

This early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…

This study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…

This Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…

This study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…

This study looks at how well a particular revision ACL surgery works over the long term. The technique uses a donor Achilles tendon and an extra stitch on the outside of the knee. Researchers will check knee function, stability, and arthritis development in 59 people who had this…

This phase 2 trial tests whether the experimental drug E6742 can reduce lupus disease activity better than a placebo. About 256 adults with lupus will take either E6742 or a placebo pill for 24 weeks. The main goal is to see if more people on E6742 achieve a meaningful reduction …

This study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…

This early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…

This study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…

This study tests a medicine called anifrolumab for people with lupus who have not taken strong immune-suppressing drugs before. The goal is to see if the drug can help patients reach remission and reduce or stop their steroid use. About 245 adults will receive weekly injections f…

This study tests an experimental drug called IMC-002 (also known as IMM0306) in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial compares the drug against a placebo, both given alongside standard care, to see if it can reduce disease …

This early-stage study tests a new treatment called CHT101 for people with severe lupus that hasn't improved with standard treatments. CHT101 uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that drive lupus. The study will enroll 15…

This study tests an experimental drug called dapirolizumab pegol for people with moderate to severe lupus. About 450 participants will receive either the drug or a placebo, added to their usual treatments. The goal is to see if the drug can improve lupus symptoms over 48 weeks.

This phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …

This study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…

This study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…

This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …

This early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …

This study follows 218 adults with systemic lupus erythematosus (SLE) in Italy who are starting anifrolumab (Saphnelo) for the first time. Researchers want to see if the drug helps patients reach a state of low disease activity while taking 5 mg or less of steroids daily. The stu…

This early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict rese…

This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the…

This early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.

This early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…

This study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…

This study tests whether a 'treat-to-target' approach—where doctors adjust treatment every 6 weeks to aim for remission—works better than usual care for people with lupus. About 606 participants who are not in remission will be followed for 120 weeks. The goal is to see if this s…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…

This early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…

This study tests if the drug sirolimus can help adults with lupus who also have very low platelet counts (a condition called immune thrombocytopenia). Participants will receive either sirolimus or a placebo for 24 weeks, then all will receive sirolimus for another 24 weeks. The g…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …

This study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This study tests the drug belimumab (Benlysta) in 30 people who were diagnosed with lupus within the last two years. Participants will receive either the drug or a placebo for one year, and then some may switch to placebo in the second year. The goal is to see if early treatment …

This early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…

This study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…

This early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…

This early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…

This phase 3 study tests whether nipocalimab can help control moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 600 adults will receive either nipocalimab or a placebo, on top of standard treatments. The main goal is to see if more people …

This early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…

This early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…

This study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …

This early study tests a new treatment called IASO207 for people with active lupus that hasn't responded to standard therapies. The treatment works by creating special immune cells inside the body to target and calm the overactive immune system. The study will check if it's safe …

This study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…

This early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see…

This study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This study tests whether a supplement called 2-HOBA can help people with lupus by lowering blood pressure and reducing harmful immune activity. About 42 women with stable lupus and mild-to-moderate high blood pressure will take either 2-HOBA or a placebo for 8 weeks, then switch.…

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 2…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This Phase 2 clinical trial is testing an investigational drug called SHR-2173 in about 248 adults with active systemic lupus erythematosus (SLE). Participants will receive either the drug or a placebo for 24 weeks, with follow-up. The main goal is to see if SHR-2173 can reduce l…

This study tests two medications, inebilizumab and blinatumomab, in adults with active lupus (with kidney inflammation) or hard-to-treat rheumatoid arthritis. The goal is to see if these drugs are safe and can help control the diseases. About 220 people will take part. This is no…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This study tests a new medicine called MIL62 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 316 adults with active lupus will receive either MIL62 or a placebo to see if it safely reduces disease activity and allows lower steroid use. The …

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…

This early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…

This phase 2 trial tests whether the experimental drug D-2570 can help people with active systemic lupus erythematosus (SLE). About 120 adults with moderate-to-severe lupus will be randomly assigned to receive either D-2570 or a placebo. The main goal is to see if D-2570 improves…

This early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …

This early-stage trial is testing a new drug, alnuctamab, in 21 people with moderate to severe lupus that hasn't improved with standard treatments. The drug is given as an injection under the skin, and participants will stay in the hospital for 9 days after the first dose. The ma…

This early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…

This early-stage study tests a single injection of a new drug, LBL-047, in healthy adults and people with mild-to-moderate systemic lupus erythematosus (SLE). The main goal is to check safety and side effects. About 112 participants will receive either the drug or a placebo. This…

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…

This early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…

This study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…

This early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…

This early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…

This study tests an experimental tablet called VENT-03 for people with active cutaneous lupus erythematosus (CLE), a condition causing painful skin rashes. Twenty-four adults will take either VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researche…

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…

This phase 2 trial tests a new drug called SG301, given as a shot under the skin, for people with systemic lupus erythematosus (SLE). About 120 participants whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo over several months. The g…

This study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…

This early-stage study tests a new drug, CPTX2309, to see if it is safe and tolerable. It involves 64 healthy adults and people with moderate to severe rheumatoid arthritis or lupus. Researchers will monitor side effects, lab results, and immune responses to determine the drug's …

This early-stage trial is testing a new drug called budoprutug (TNT119) in 30 adults with active systemic lupus erythematosus (SLE). The main goal is to check the drug's safety and how the body processes it. Participants will receive a single dose of the drug by IV, and researche…

This early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…

This early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …

This early-stage study tests a new mRNA-based treatment (ABO2203) for people with autoimmune diseases that haven't improved with standard care. The therapy works by directing the body's immune cells to attack and control overactive immune cells causing the disease. The study will…

This early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…

This phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The go…

This early-stage trial tests a new treatment called AFN50 for people with autoimmune diseases that haven't responded to standard therapies. AFN50 is a type of CAR T-cell therapy designed to target and destroy faulty immune cells. The study will enroll 18 adults to check if the tr…

This study is testing the long-term safety of a drug called ianalumab in people with lupus who have already completed a previous study with the same drug. About 550 participants will receive either ianalumab or a placebo monthly or quarterly for up to several years. The main goal…

This early-phase study tests a new treatment called Meta10-19 for people with moderate to severe systemic lupus erythematosus (SLE). The therapy uses a patient's own immune cells, modified to better target and destroy faulty B cells that drive the disease. The main goals are to f…

This study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to s…

This early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…

This early study tests the safety of a new biologic drug called STR-P004 in 39 adults with autoimmune diseases that have not responded to standard treatments. Participants receive the drug by IV infusion, and researchers monitor for side effects and how the drug behaves in the bo…

This study tests a new biologic drug called GR1803 in 44 people with systemic lupus erythematosus, an autoimmune disease. The main goal is to check safety and see if the drug can control lupus activity. Participants must have moderate to severe lupus and have tried standard treat…

This early-stage study tests a new injection called AFN50 in 18 adults with autoimmune diseases like lupus. The main goal is to check safety and see how the body reacts, including changes in immune cells. Participants must have active disease despite standard treatments.

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…

This early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…

This phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…

This study looks at whether people aged 60 and older with stable lupus can safely stop taking hydroxychloroquine, a common medication that can cause eye damage over time. About 330 participants will either continue the drug or switch to a placebo and be monitored for one year. Th…

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…

This early-stage study is testing a new treatment called PTOC1 cells, which are a type of CAR-T cell therapy, for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified in a lab …

This study tests a new drug, YK012, in people with moderate to severe systemic lupus erythematosus (SLE). The drug is designed to target certain immune cells. The trial will check for safety, side effects, and early signs that the drug might help control lupus. About 189 adults a…

This early-stage trial tests a new type of CAR-T cell therapy for people with refractory systemic lupus erythematosus (SLE), a severe form of the autoimmune disease. The treatment uses a patient's own immune cells, modified to target two proteins (BCMA and CD70) on harmful cells.…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-phase trial is testing a new treatment for children with B cell-related autoimmune diseases like lupus and kidney disease. The therapy uses specially engineered natural killer (NK) cells that target and destroy faulty immune cells. Only 12 children will take part, and …

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This early-stage trial is testing a new treatment called LUCAR-G79D for people with lupus or inflammatory myopathies that haven't responded to standard therapies. The treatment involves giving patients specially engineered immune cells to help control their disease. The study is …

This study compares telitacicept, a newer biologic drug, against the standard treatment cyclophosphamide for lupus patients who also have interstitial lung disease (ILD). About 100 adults with early lupus and ILD will receive either telitacicept or cyclophosphamide, plus usual ca…

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…

This early-stage trial tests a new medicine called IMSB301 in people with rare diseases where the immune system attacks the body. The study includes up to 6 participants aged 12 and older. The main goal is to check if the drug is safe and how it behaves in the body.

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…

This early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the d…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…

This early-phase study is testing a new type of immunotherapy called universal CAR-T cells in 12 people with moderate to severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells driving the disease. The main goals…

This Phase 1 trial tests a new, fast-made CAR-T cell therapy for people with refractory systemic lupus erythematosus (SLE) who haven't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack lupus-causing cells. The study wi…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…

This study tests whether the shingles vaccine (Shingrix) is safe and triggers a good immune response in people with lupus, a condition that affects the immune system. About 224 adults with lupus will receive either the vaccine or a placebo, and researchers will monitor for lupus …

This early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goals are to check…

This study tests a new drug called APG-2575 in 40 people with mild-to-moderate lupus. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to check safety and how the body processes the drug, not yet to see if it improves lupus symptoms.

This early-stage trial tests a new treatment for children and young adults (ages 2-30) with severe lupus that hasn't responded to standard therapies. The treatment involves collecting a patient's own immune cells, engineering them to target and destroy faulty B cells (which drive…

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…

This early-stage trial tests a new treatment made from donated umbilical cord blood cells, designed to target and calm the overactive immune system in adults with severe lupus that hasn't responded to standard therapies. About 48 participants will receive the therapy to see if it…

This early-phase trial is testing a new type of cell therapy (CAR-NK cells) in 36 children with B-cell-related autoimmune diseases like lupus and certain kidney diseases. The therapy uses specially designed immune cells to target and potentially control the overactive immune syst…

This early trial tests if blinatumomab, a drug used for certain blood cancers, can help children with severe lupus that hasn't improved with other treatments. Six children will receive two short courses of the drug and be monitored for a year. The main goals are to check safety a…

This study tests an experimental drug called SSGJ-626, an antibody that targets a protein on certain immune cells, in people with systemic lupus erythematosus (SLE). The trial will enroll 198 adults aged 18-70 with SLE. Participants will receive either the drug or a placebo as a …

This trial is testing a treatment called MB-CART19.1, which uses a patient's own immune cells that are modified in a lab to target and destroy faulty cells involved in lupus. It is for adults with severe lupus that has not improved with standard treatments. The study will first f…

This Phase 3 trial tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus nephritis without the need for oral steroids. About 196 people with active lupus kidney disease will be randomly assigned to either the obinutuzumab/MMF regim…

This early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune response…

This early-phase study tests whether a new drug called ONT01 is safe for people with lupus nephritis or systemic lupus erythematosus (SLE). About 61 participants will receive ONT01 alongside their usual lupus medications. The goal is to find the highest safe dose and see if it im…

This early-stage trial tests a new 'ultra-fast' version of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack faulty immune cells driving the disease. The stud…

This early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have ac…

This study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…

This study follows 300 people with active systemic lupus erythematosus (SLE) who are taking anifrolumab, a drug that blocks a key immune signal. Researchers will track how many achieve remission or low disease activity over 5 years, as well as side effects and quality of life. Th…

This study tests a program called CO-LEAD that trains doctors to use effective communication strategies and a patient survey to identify barriers to taking lupus medications. Researchers will enroll 480 patients and their clinicians at two academic centers. The goal is to see if …

This trial tests a one-time treatment using a patient's own immune cells, engineered to target and destroy B cells, which drive autoimmune diseases like lupus, scleroderma, and myositis. 24 adults with active disease will receive the therapy after a short chemotherapy. The main g…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…

This early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…

This early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…

This early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune syste…

This early-stage study tests a new drug, CC312, in 32 adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants receive either CC312 or a placebo intravenously to check for safety, side effects, and how the drug moves through the body. The goal is to see if …

This early-stage trial is testing a new drug called A-319 in 25 people with active or treatment-resistant systemic lupus erythematosus (SLE). A-319 is a type of antibody designed to target and help control the immune system cells that drive lupus. The main goal is to see if the d…

This early-phase trial is testing whether a single injection of stem cells from donated umbilical cords is safe for people with active lupus. Ten adults will receive the cells alongside their usual care. Researchers will monitor side effects and check for signs that lupus activit…

This study is tracking 684 people with lupus to see if the drug belimumab can prevent serious organ damage (called BILAG A flares) better than standard care alone. Researchers are using real-world data from clinics in Greece, comparing patients on belimumab to those on usual trea…

This study looks at whether two simple blood markers—albumin-to-globulin ratio and prognostic nutritional index—can help predict disease activity in people with lupus. Researchers will measure these markers in 200 participants and compare them with standard disease activity score…

This study is testing a new blood test (the HMEC test) to see if it can better identify which patients with thrombotic microangiopathy (TMA) have a specific immune system problem driving their disease. TMA is a severe condition that damages kidneys and the brain. The researchers …

This study tests a new skin test (C-TST) to find hidden tuberculosis (TB) infection in people with rheumatic diseases like rheumatoid arthritis who are about to start powerful medications called biologics. These drugs can reactivate dormant TB, so accurate screening is critical. …

This study is testing whether a urine test can detect lupus nephritis, a serious kidney complication of lupus, as accurately as a standard kidney biopsy. Researchers will collect urine and blood samples from 40 lupus patients with kidney problems and compare the results to their …

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…

This study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…

This study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…

This study compares two online treatments for chronic pain: an 8-week cognitive behavioral therapy program (16 hours total) and a single 2-hour pain relief skills class. Researchers want to see which works better for reducing pain intensity and interference. The study will enroll…

This study tests a short behavioral treatment delivered over Zoom to help adults with fibromyalgia, lupus, chronic pelvic pain, or chronic low back pain. The goal is to reduce pain, disability, and related issues like anxiety or depression. Participants will learn strategies to m…

This study tests whether online group programs to manage fatigue can help people with lupus. Participants will either receive a fatigue booklet alone or also attend online group sessions (4 or 7 weeks long). The goal is to see if the programs reduce fatigue impact and improve qua…

This study is testing a new telehealth program designed to support brain health in teenagers with childhood-onset lupus. The program teaches problem-solving, emotion regulation, and communication skills over 10 online sessions. Researchers want to see if the program is practical …

This study looks at how three different levels of physical activity—45, 90, or 150 minutes per week—affect arthritis symptoms like pain and mobility. Researchers will enroll 285 adults with arthritis, rheumatoid arthritis, gout, fibromyalgia, osteoarthritis, or lupus. Participant…

This study tests an online wellness course that teaches diet, exercise, stress reduction, and self-care to people with rheumatoid arthritis, lupus, Sjogren's syndrome, and similar conditions. Researchers want to see if the program reduces fatigue and improves quality of life. Abo…

This study tests if a type of talk therapy called Emotional Awareness and Expression Therapy (EAET) can help reduce widespread pain in people with lupus. Thirty adults with lupus and fibromyalgia or chronic pain will attend 8 weekly online sessions. Researchers will check if the …

This study is testing a program called TEACH that teaches coping skills to young people (ages 12-22) with childhood-onset lupus. The goal is to see if it helps reduce common symptoms like fatigue, pain, and depression. About 175 participants will take part, and the program is des…

This study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …

This study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…

This study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…

This study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …

This study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…

This study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…

This study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …

This study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…

This study is measuring a protein called STIM1 on the surface of immune cells in 670 people with various autoimmune diseases. The goal is to find which diseases have high levels of this protein, which could help researchers develop new antibody-based treatments. Participants prov…

This study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.

This study aims to learn more about the causes of rheumatic diseases—conditions that cause joint pain, stiffness, and swelling—and why they often affect minority groups more severely. Researchers will observe up to 7,500 adults with known or suspected rheumatic disease, providing…

This study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …

This study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…

This study follows 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab (Saphnelo) during pregnancy affects the health of mothers or their babies. Researchers will compare women who took the drug during pregnancy to those who did not, tracking bi…

This study is collecting joint fluid and tissue samples from 50 adults with inflammatory or non-inflammatory bone and joint diseases. Researchers will use both standard and advanced lab techniques to find new biomarkers that could help diagnose rheumatic diseases more accurately …

This study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …

This study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …

This study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…

This study follows 4,000 people with interstitial lung disease (including conditions like pulmonary fibrosis and sarcoidosis) to understand how the disease naturally changes over time. Researchers will collect medical data and blood samples, and compare them to a healthy control …

This study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.

This study looks at 600 teens and young adults (ages 14-26) with conditions like juvenile arthritis, fibromyalgia, or past surgeries to understand why some develop long-lasting pain while others don't. Researchers will examine pain sensitivity, immune markers, and social factors …

This study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…

This study looks at how a type of cell death called ferroptosis, which is driven by iron, might play a role in lupus. Researchers will take blood samples from 120 people with lupus and compare them to people with other autoimmune diseases. The goal is to find new clues for future…

This study looks at blood clotting in people with autoimmune skin diseases like bullous pemphigoid and lupus. Researchers will collect blood samples from 39 participants—some with active disease and some with mild or controlled disease—plus 15 healthy controls. They will measure …

This study is collecting health information, lifestyle data, and biological samples from up to 100,000 adults to help researchers better understand diseases like lupus, celiac disease, and kidney disease. Participants provide data and samples through a direct-to-patient platform.…

This study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…

This study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…

This study looks at specific immune cells (iNKT cells and monocytes) in people with lupus to see how certain receptors on these cells change when the disease is active versus stable. Researchers will collect extra blood samples from 50 lupus patients during routine visits. The go…

This study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound. The goal is to identify which children are at higher risk for heart issues. No new treatments are being tested.

This observational study is following 700 pregnant women with lupus or antiphospholipid syndrome across nine medical centers. Researchers are looking at specific proteins in the blood to see if they can predict serious pregnancy complications like fetal death, preterm delivery, o…

This study looks at young adults with chronic inflammatory rheumatic diseases who are moving from pediatric to adult healthcare. Researchers want to see if a structured program that includes education workshops and joint doctor visits helps patients manage their own care better. …

This study collects and freezes testicular tissue from boys and young men who are at risk of becoming infertile due to cancer, autoimmune disorders, or their treatments. The tissue is stored in a research bank, with the hope that future medical advances will allow it to be used t…

This study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…

This observational study is working to create a more objective way to measure pain in children with juvenile idiopathic arthritis, lupus, or fibromyalgia. Researchers will follow 90 participants for one year, collecting data during regular clinic visits. The goal is to develop a …

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study is building a database of 700 people with cutaneous lupus erythematosus (CLE) to track how often it occurs and how severe it gets. Researchers at the University of Pennsylvania and UT Southwestern are collecting information over time. No new treatments are being tested…

This study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…

This study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …

This study is testing whether giving the COVID-19 booster and flu vaccine at the same time is as good as giving them a month apart for people with weakened immune systems. It also compares getting a COVID-19 booster every 3 months versus every 6 months. The trial involves 660 adu…

This study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…

This study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…

This study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…

This study looks at how changes in the TREX1 gene are linked to lupus, especially skin problems. Researchers will check disease activity in 90 adults with lupus using a standard scoring tool. No new treatment is given; the goal is to better understand the disease.

This study is a registry that will follow 1,000 adults with systemic lupus erythematosus (SLE) during their regular doctor visits. Researchers will collect information on how lupus is managed and how patients respond to treatments over time. The goal is to better understand the d…

This study is a fully online registry for adults and children with lupus. Participants fill out surveys every six months about their symptoms, treatments, and quality of life. The goal is to collect real-world data to improve care and guide future research. No travel or clinic vi…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study is developing a patient-reported outcome measure (PROM) to assess how steroids affect the quality of life of children and young people with rheumatic conditions. Researchers will hold focus groups and interviews with 70 participants and their families to create and tes…

This study is observing children with childhood-onset lupus who are receiving an experimental therapy called a bispecific T-cell engager. Researchers will take blood samples over time to track how the immune system changes. The goal is to find patterns that could help monitor the…

This study looks at why some lupus patients get false positive results on tests for HLA antibodies, which can make it harder to get an organ transplant. Researchers will study 30 adults with lupus who have no known risk factors for these antibodies. The goal is to find better way…

This registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…

This study is creating a registry of 1,000 people with lupus (systemic lupus erythematosus or cutaneous lupus) to collect health information and blood samples over time. The goal is to learn how lupus changes and find better ways to treat it. Participants must be patients at Duke…

This study looks at pregnancy outcomes in 50 women who had at least one pregnancy before being diagnosed with lupus. Researchers will collect data from medical records and interviews to see how often pregnancy complications occurred before the lupus diagnosis. The goal is to bett…

This study looks at how natural cannabis compounds (phytocannabinoids) affect immune cells from 100 people with chronic inflammatory diseases like rheumatoid arthritis, lupus, and Crohn's disease. Researchers will take a blood sample and expose the cells to different cannabis ext…

This study is not a treatment trial. It aims to collect blood samples from 400 children and their relatives who have rare autoimmune or autoinflammatory diseases (like lupus or juvenile arthritis). Researchers will analyze the samples to find genetic mutations that cause these co…

This study aims to learn more about rare genetic diseases that affect both the immune system and the nervous system. Researchers will collect medical information and samples from 1,000 participants, including patients, their relatives, and healthy volunteers. The goal is to bette…

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study aims to collect genetic and protein data from 1,000 people with lupus-related skin disease. Researchers hope to identify the genes and proteins that cause skin lesions in lupus. The goal is to better understand the disease, improve diagnosis, and spark new drug develop…

This study looks at how immune cells and inflammatory molecules differ in people with migraine, especially those who also have autoimmune diseases like multiple sclerosis, rheumatoid arthritis, or endometriosis. Researchers will compare blood samples from 396 women to measure reg…

This study is an online survey for 1,000 adults diagnosed with a rheumatic or musculoskeletal disease living in a EULAR country. Participants will answer periodic questionnaires about their healthcare, social life, and work. The goal is to gather real-world data to help researche…

This observational study follows up to 20,000 children and young adults with pediatric-onset rheumatic diseases, such as juvenile idiopathic arthritis. Researchers collect data on treatments, safety, and long-term outcomes to better understand these conditions. The registry does …

This study will examine chest CT scans from 500 adults with rheumatoid arthritis, connective tissue diseases, or idiopathic pulmonary fibrosis to better understand lung disease patterns. Researchers want to see which scan features are most common in rheumatoid arthritis-related i…

This study is collecting blood, urine, and stool samples from 500 children with autoimmune diseases and healthy controls. Researchers will analyze these samples to find molecular patterns that could help diagnose these conditions and guide treatment decisions. The goal is to crea…

This study looks at whether lupus makes the immune system age faster. Researchers will take blood samples from 75 lupus patients to measure changes in immune cells and telomeres (a marker of aging). The goal is to better understand how lupus affects the body over time.

This study looks at whether doing a repeat kidney biopsy one year after starting treatment for lupus nephritis can help doctors decide if more treatment is needed. Half of the 206 participants will get the repeat biopsy, and the other half will follow standard care. The goal is t…